Fig. 5: Prognostic power of tumor differentiation (TD) and basal-luminal gene expression signatures. | Communications Biology

Fig. 5: Prognostic power of tumor differentiation (TD) and basal-luminal gene expression signatures.

From: Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy

Fig. 5

a, b Heatmaps of gene expression of 42 basal-luminal genes (including 18 TD genes) in the 6 retrospective study cohorts (MDA1, MDA2, LU, CNU, MSK, CIT) (a) and the 2 clinical trial cohorts (MVAC, MVAC + B) (b). c, d Patient overall survival stratified by the basal and Luminal subtypes defined by the 42 basal-luminal genes in the 6 retrospective study cohorts (c) and the 2 clinical trial cohorts (d). e, f Patient overall survival stratified by the basal and differentiated subtypes defined by the 18 TD genes in the 6 retrospective study cohorts (e) and the 2 clinical trial cohorts (f). MDA1: MD Anderson Cancer Center (USA) cohort 1; MDA2: MDA cohort 2; LU: Lund University, Sweden; CNU: Chungbuk National University, South Korea; MSK: Memorial Sloan-Kettering Cancer Center, USA; CIT: Curie Institute, France; MVAC: methotrexate, vinblastine, doxorubicin, and cisplatin; B: bevacizumab. Log-rank test was used to compare subtype-specific survival curves.

Back to article page